While many pharmacological treatments for depression increase monoaminergic and BDNF signaling, they fail to address the other potential neurobiological contributors to depression, such as deficiencies in glutamatergic signaling and overactivity of the lateral habenula [1,2]. Here, BDNF is linked to depressive disorder.